2
Orphan Designations
0 approved, 2 designated
0
FDA Approvals
2
Active Trials
200 recruiting
3
Rare Diseases
across 4 areas
1
News (30d)
Capricor, Inc. is a company with 2 orphan drug designations across 3 rare diseases. Active clinical trials in 2 indications. 5 active policy bills affect their portfolio. 1 news article in the past 30 days.
Disease-by-disease pipeline progression from orphan designation through clinical trials to FDA approval.
Source: FDA Orphan Drug Designations, ClinicalTrials.gov, Drugs@FDA
| Disease | Drug(s) | Stage |
|---|---|---|
| Becker muscular dystrophy | human allogeneic cardiosphere-derived cells | Des.TrialAppr. |
| Duchenne muscular dystrophy | allogeneic cardiosphere-derived cells | Des.TrialAppr. |
| muscular dystrophy | - | Des.TrialAppr. |
0% of portfolio targets high unmet need diseases
48
overlap in 2+ diseases
0/3
candidate diseases
1
avg importance: 70
5
affecting portfolio
0% of portfolio targets high unmet need diseases
48
overlap in 2+ diseases
0/3
candidate diseases
1
avg importance: 70
5
affecting portfolio